Public Profile

Viatris

Viatris Inc., a global healthcare company formed through the merger of Mylan and Upjohn, is headquartered in the United States. Established in 2020, Viatris operates in over 165 countries, focusing on the pharmaceutical industry with a commitment to providing access to high-quality medicines. The company’s core business areas include generic and specialty pharmaceuticals, biosimilars, and over-the-counter products. Viatris is renowned for its extensive portfolio, which features a diverse range of medications that address various health conditions, including chronic diseases and infectious diseases. Its unique approach combines a broad product offering with a strong emphasis on patient access and affordability. With a significant market presence, Viatris has achieved notable milestones, including the successful integration of its legacy companies and a commitment to sustainable healthcare solutions.

DitchCarbon Score

How does Viatris's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

49

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Viatris's score of 49 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.

82%

Let us know if this data was useful to you

Viatris's reported carbon emissions

In 2023, Viatris reported total greenhouse gas (GHG) emissions of approximately 751,600,000 kg CO2e, comprising 335,600,000 kg CO2e from Scope 1 and 416,100,000 kg CO2e from Scope 2 emissions. The company has set ambitious targets to reduce its GHG emissions, committing to a 42% reduction in absolute Scope 1 and 2 emissions by 2030, using 2020 as the baseline year. Additionally, Viatris aims to cut its absolute Scope 3 emissions, which include purchased goods and services, capital goods, and upstream transportation, by 25% within the same timeframe. In the UK, Viatris has also pledged to support a net-zero ambition by 2050, further demonstrating its commitment to sustainability. The company's targets align with the Science Based Targets initiative (SBTi) and are designed to contribute to global efforts to limit warming to 1.5°C. Viatris's emissions data and reduction initiatives reflect its proactive approach to addressing climate change and enhancing its environmental responsibility.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

201520162017201820192020202120222023
Scope 1
299,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
Scope 2
354,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
Scope 3
653,000,000
000,000,000
000,000,000
000,000,000
000,000,000
0,000,000,000
-
0,000,000,000
-

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Viatris's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Viatris is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Viatris is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Zoetis

US
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Shasun Pharmaceuticals Limited

IN
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Sai Life Sciences

IN
Medical, precision and optical instruments, watches and clocks (33)
Updated 4 days ago

Sandoz

CH
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Teva Pharmaceuticals

IL
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Regeneron

US
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers